drugs

The Catalan Institute of Oncology (ICO) and Roche pharmaceutical company have signed an agreement stating that the Catalan public institute will pay for treatments against cancer depending on clinical results adapted to each specific patient. For now, the agreement provides that Roche will supply two drugs against the most common cancers, mostly breast and colon. According to the agreement, the probabilities of success will be thoroughly examined and if they meet the requirements, the Catalan Government will fully pay for the treatment. If not, Roche will assume the costs progressively according to the degree of success.

The extensive Catalan Police operation against drug trafficking in Barcelona’s Zona Franca quarter and in Sant Adrià de Besós’ (North of Barcelona) ‘La Mina’ neighbourhood resulted in 33 arrests and 29 homes searched. With 300 police officers deployed from 7 different police areas, this operation was the largest-ever made by the Catalan Government’s police corps in terms of officers deployed. Catalan Minister for Home Affairs, Ramon Espadaler, stated that further arrests could still be announced in the following days. The investigation leading to this operation had begun in December 2012.

Compared to a year ago, the Catalan Healthcare System spent 24.6% less last July than in the same month of 2011. In July 2011, Catalonia spent €143.52 million on pharmaceutical products while it spent €108.10 million last month, when the drug prescription fee began and citizens started to pay a greater share of the cost of prescription drugs. Furthermore, drug prescriptions fell by 20%. In the whole of Spain, pharmaceutical spending also decreased by 24% last July, compared to a year ago.

The Spanish Social Security has published the list with the 417 drugs that from September will no longer be subsidised in order to reduce public spending and meet deficit targets. Most of them are some of the most consumed medicines for minor symptoms, such as heartburn, muscle pain, or diarrhoea. Since the measure is not popular among doctors, the Catalan Health Minister, Boi Ruiz, said that more expensive drugs with similar effects but not included in the list may now be prescribed, which would increase pubic healthcare spending instead of reducing it.

The Catalan pharmaceutical company Grifols, the third world leader in the production of blood plasma based technologies, has seen its turnover increase by 15% in the first half of 2012 to €1.32 billion. Its net profit for the first half of 2012 was €133.5 million, seven times that of the previous year. The company’s success is attributed to its wide geographical consumer base and the recent purchase of US based Talecris Plasma Resources.

Set in the Gothic district, the museum is designed to explain to its visitors the secrets of marihuana and in fact it clearly advocates for the legalization of this drug. In the inauguration day, Duch businessman Ben Dronkers was joined by Virgin owner Richard Branson, who thinks that marihuana can help the country out of the crisis

Rasquera, with less than one-thousand residents and located in southern Catalonia, approved on April 10th planting cannabis as part of their local economic reactivation plan through a citizen vote. The day after, Rasquera’s Mayor announced he will resign as his proposal did not reach 75% of the popular support. However, he said the plan will carry on. The Catalan Minister for Home Affairs affirmed that the police will report to the public attorney on any cannabis plantation, since they continue being illegal despite Rasquera’s vote. The Spanish Justice Minister thought that the initiative could have “more negative consequences in the long run” than “positive in the short term”.

The Spanish Government temporary reduces the VAT on new flat’s purchase, asks the largest and profitable companies to advance money from their corporate tax, and obliges doctors to prescribe generic drugs and not brands. With all those measures, the Spanish Government expects to get 4,900 million extra euros until the end of the year.

The new drug, called ‘Eribulin’, improves the survival rate of patients with a metastasis from breast cancer by 20%. The drug has been developed by a multinational team lead by staff from Barcelona’s Vall d’Hebron Hospital. The study has been published in the reference medical journal ‘The Lancet’.

Catalan researchers from the Universitat Autònoma de Barcelona claim the new substance could be used to treat stress, phobias or depression. The drug development was done in cooperation with the Emory University in the US. The new drug still has to go through a long testing process.

The Catalan police uncovered a laboratory with over 200,000 pills whose active ingredient provokes a serious health risk.